Cancer Research and Treatment

Hematologic malignancy

The Role of Direct Oral Anticoagulants in Managing Myeloproliferative Neoplasms Patients: Ji Yun Lee, Ju-Hyun Lee, Woochan Park, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang; Cancer Res Treat. 2025;57(2):612-620. Published online September 20, 2024; DOI: https://doi.org/10.4143/crt.2024.738

Abstract PDF Supplementary Material PubReader ePub

Purpose
Thrombosis and bleeding significantly affect morbidity and mortality in myeloproliferative neoplasms (MPNs). The efficacy and safety of direct oral anticoagulants (DOACs) in MPN patients remain uncertain.
Materials and Methods
We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service database from 2010 to 2021.
Results
Out of the 368 MPN patients included in the final analysis, 62.8% were treated with DOACs for atrial fibrillation (AF), and 37.2% for venous thromboembolism (VTE). The AF group was statistically older with higher CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke, transient ischemic attack, or thromboembolism, vascular disease, age 65-74 years, sex category [female]) scores compared to the VTE group. Antiplatelet agents were used in 51.1% of cases, and cytoreductive drugs in 79.3%, with hydroxyurea being the most common (64.9%). The median follow-up was 22.3 months, with 1-year cumulative incidence rates of thrombosis and bleeding at 11.1% and 3.7%, respectively. Multivariate analysis identified CHA2DS2-VASc scores ≥ 3 (hazard ratio [HR], 3.48), concomitant antiplatelet use (HR, 2.57), and cytoreduction (HR, 2.20) as significant thrombosis risk factors but found no significant predictors for major bleeding.
Conclusion
Despite the limitations of retrospective data, DOAC treatment in MPN patients seems effective and has an acceptable bleeding risk.

Citations

Citations to this article as recorded by

Survey of Clinical Practice in Chronic Myeloproliferative Neoplasms in Croatia: A Study by the MPN Working Group Party of the Croatian Cooperative Group for Hematologic Diseases (KROHEM)
Ivan Krecak, Marko Lucijanic, Rajko Kusec
Journal of Clinical Medicine.2025; 14(5): 1524. CrossRef

1,535 View
128 Download
1 Web of Science
1 Crossref

Diagnostic Laparoscopy of Patient with Deep Vein Thrombosis before Diagnosis of Ovarian Cancer : A Case Report: Jae Eun Ha, Yong Seok Lee, Hae Nam Lee, Eun Kyung Park; Cancer Res Treat. 2010;42(1):48-52. Published online March 31, 2010; DOI: https://doi.org/10.4143/crt.2010.42.1.48

Abstract PDF PubReader ePub

Venous thromboembolism (VTE) is a common complication in patients with malignant disease. Epidemiological studies have demonstrated an increased risk of subsequent cancer in the patients who are diagnosed with idiopathic venous thrombosis. Cancers of the breast, lung and ovary in women and adenocarcinomas of an unknown primary cancer are most strongly associated with thrombosis. Mucin-producing cancers are most often associated with VTE and the highest rates of VTE were found for cases of ovarian cancer, but the absolute risk of cancer after thrombosis is relatively low (about 2% over the first year) and so the benefit of screening for cancer in thrombosis patients seems limited. But as this case, the association between thrombosis and occult cancer shows the importance of this association for patients who have thrombosis that is unresponsive to anticoagulant therapy. Especially, we should recognize that such patients can undergo investigation for an underlying malignancy. Diagnostic laparoscopy of an adnexal mass for confirming cancer in the acute setting of deep vein thrombosis (DVT) was performed for our patient. We report here on a case of a patient with DVT in the upper and lower extremities before the diagnosis of ovarian cancer, and we briefly review of the relevant literature.

Citations

Citations to this article as recorded by

Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy
Qinhui Dong, Xiayin Zhu, Yafen Gao, Zhengrong Wang, Dexing Zheng, Jian Zhu, Pan Zheng
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer Patient
Masahito Naito, Ryota Torii, Yuki Hashimoto, Yuki Kawamoto, Kenichi Hayashi, Hiroaki Shinoda, Yumiko Honjo, Motoki Hiroyoshi
Chemotherapy.2019; 64(3): 163. CrossRef
Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review
HONGWEI SHEN, JIANHONG SHANG, GANG NIU, JUN LIU, ZESHAN YOU, SHANYANG HE
Oncology Letters.2015; 10(4): 2579. CrossRef

8,456 View
59 Download
3 Crossref

Aggressive Surgical Resection of Hepatocellular Carcinoma with Bile Duct Tumor Thrombosis: Hong Jin Kim, Yong Sung Jeon, Min Chul Chim, Koing Bo Kwun; J Korean Cancer Assoc. 1995;27(3):411-419.

Abstract PDF: In hepatocellular carcinoma the obstructive jaundice due to tumor infiltration, hemobilia, or tumor compression is uncommon clinial feature. Only a few cases have been reported, aince Mallory reported the first case in 1947. The prognosis of hepatocellular carcinoma with bile duct tumor thrombosis has been report- ed to be very poor. And most of the treatment used to be palliative procedures. such as T-tube decompression, ligation of hepatic ertery, or tranaarterial embolization. Recently, the refinement of surgical technique and perioperative metabolic management caused massive hapatic resection to be performed safely. From June 1984 to March l995, 88 patients with hepatocellular carcinoma underwent operation at the Youngnam University Medical Center. Of them, 6 patients manifested with jaundice due to bile duct tumor thrombosis. We performed hepatectomy for 4 patients, and tumor embo- lectomy with T-tube decompression for 2 patients. Among them, 2 patients who had received hepatectomy survived more than 2 years. In conclusion the aggressive surgical approach for the hepatocellular carcinoma presenting as an obstructive jaunding secondary to tumor thrombosis in the bile duct should be considered for long term survivaL

2,497 View
12 Download

Ductal Carcinoma in situ of the Breast: Jeoung Won Bae, Bum Hwan Koo; J Korean Cancer Assoc. 1995;27(3):419-426.

Abstract PDF: In hepatocellular carcinoma the obstructive jaundice due to tumor infiltration, hemobilia, or tumor compression is uncommon clinial feature. Only a few cases have been reported, aince Mallory reported the first case in 1947. The prognosis of hepatocellular carcinoma with bile duct tumor thrombosis has been reported to be very poor. And most of the treatment used to be palliative procedures. such as T-tube decompression, ligation of hepatic ertery, or tranaarterial embolization. Recently, the refinement of surgical technique and perioperative metabolic management caused massive hapatic resection to be performed safely. From June 1984 to March l995, 88 patients with hepatocellular carcinoma underwent operation at the Youngnam University Medical Center. Of them, 6 patients manifested with jaundice due to bile duct tumor thrombosis. We performed hepatectomy for 4 patients, and tumor embolectomy with T-tube decompression for 2 patients. Among them, 2 patients who had received hepatectomy survived more than 2 years. In conclusion the aggressive surgical approach for the hepatocellular carcinoma presenting as an obstructive jaunding secondary to tumor thrombosis in the bile duct should be considered for long term survivaL

2,439 View
13 Download

Search